PRIOR AUTHORIZATION POLICY
POLICY: Metabolic Disorders – Betaine Anhydrous Prior Authorization Policy
• Cystadane® (betaine anhydrous powder – Recordati Rare
Diseases, generic)
REVIEW DATE: 09/11/2024
INSTRUCTIONS FOR USE
THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA
COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE
DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE
CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS
ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP
SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN
DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR
EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE
POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE
COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY
DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE
REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY
APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE
SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL
DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE
DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES
ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,
DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.
CIGNA NATIONAL FORMULARY COVERAGE:
OVERVIEW
Betaine anhydrous powder (Cystadane, generic), a methylating agent, is indicated
for the treatment of homocystinuria to decrease elevated homocysteine blood
concentrations in adults and pediatric patients.1 Included within the category of
homocystinuria are cystathionine beta-synthase deficiency, 5,10-
methylenetetrahydrofolate reductase deficiency, and cobalamin cofactor metabolism
defect.
Disease Overview
Homocystinuria is a group of rare, autosomal recessive disorders caused by
mutations in specific enzymes that metabolize amino acids.2,3 Elevated levels of
homocysteine can lead to abnormalities in the central nervous system, eye, skeletal
system, and vascular system.
Clinical Efficacy
Clinical and observational studies demonstrated patients with homocystinuria who
received betaine anhydrous powder had significant reductions plasma homocystine
or homocysteine concentrations.1 Additionally, improvement in seizures or
behavioral and cognitive functioning were reported for many patients. Many of these
Page 1 of 3 - Cigna National Formulary Coverage - Policy:Metabolic Disorders – Betaine Anhydrous Prior
Authorization Policy
patients were also taking other therapies such as vitamin B6 (pyridoxine), vitamin
B12 (cobalamin), and folate with variable biochemical responses.
POLICY STATEMENT
Prior Authorization is recommended for prescription benefit coverage of betaine
anhydrous powder (Cystadane, generic). All approvals are provided for the duration
noted below. Because of the specialized skills required for evaluation and diagnosis
of patients treated with betaine anhydrous powder (Cystadane, generic) as well as
the monitoring required for adverse events and long-term efficacy, approval requires
betaine anhydrous powder (Cystadane, generic) to be prescribed by or in consultation
with a physician who specializes in the condition being treated.
• Cystadane® (betaine anhydrous powder – Recordati Rare Diseases,
generic)
is(are) covered as medically necessary when the following criteria is(are)
met for FDA-approved indication(s) or other uses with supportive evidence
(if applicable):
FDA-Approved Indication
1. Homocystinuria. Approve for 1 year if the patient meets the following (A, B, and
C):
A) Patient has a confirmed diagnosis based on genetic testing demonstrating one
of the following (i, ii, or iii):
i. Cystathionine beta-synthase deficiency; OR
ii. 5,10-methylenetetrahydrofolate reductase deficiency; OR
iii. Cobalamin cofactor metabolism defect; AND
B) Patient has tried or is concurrently receiving vitamin B6 (pyridoxine), vitamin
B12 (cobalamin), or folate supplementation; AND
C) The medication is prescribed by or in consultation with a geneticist, metabolic
disease specialist, or a physician who specializes in the management of
homocystinuria.
CONDITIONS NOT COVERED
• Cystadane® (betaine anhydrous powder – Recordati Rare Diseases,
generic)
is(are) considered experimental, investigational or unproven for ANY other
use(s); criteria will be updated as new published data are available.
REFERENCES
1. Cystadane® powder [prescribing information]. Lebanon, NJ: Recordati Rare Diseases; October
2019.
3 Pages - Cigna National Formulary Coverage - Policy:Metabolic Disorders – Betaine Anhydrous Prior
Authorization Policy
2. Truitt C, Hoff WD, Deole R. Health functionalities of betaine in patients with homocystinuria. Front
Nutr. 2021 Sep 9;8:690359.
3. Morris A, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine
beta-synthase deficiency. J Inherit Metab Dis. 2017 Jan;40(1):49-74.
HISTORY
Type of Summary of Changes Review
Revision Date
Annual No criteria changes. 08/30/2023
Revision
Annual No criteria changes. 09/11/2024
Revision
"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are
provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance
Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health
Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna
Group.
3 Pages - Cigna National Formulary Coverage - Policy:Metabolic Disorders – Betaine Anhydrous Prior
Authorization Policy